CN106492073A - 一种具有降尿酸功效的中药组合物及其制备方法和应用 - Google Patents
一种具有降尿酸功效的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN106492073A CN106492073A CN201611255698.7A CN201611255698A CN106492073A CN 106492073 A CN106492073 A CN 106492073A CN 201611255698 A CN201611255698 A CN 201611255698A CN 106492073 A CN106492073 A CN 106492073A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- herba hordei
- lour
- merr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title abstract description 50
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract description 46
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract description 44
- 229940116269 uric acid Drugs 0.000 title abstract description 44
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 43
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 43
- 241000218176 Corydalis Species 0.000 claims abstract description 34
- 201000005569 Gout Diseases 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 33
- 239000000284 extract Substances 0.000 claims description 30
- 239000000469 ethanolic extract Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 201000001431 Hyperuricemia Diseases 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012467 final product Substances 0.000 description 8
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 3
- 229960005101 febuxostat Drugs 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241001313868 Arundina Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 241001558017 Gynura Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000366676 Justicia pectoralis Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- CPWPJLJWUXOOAB-UHFFFAOYSA-N benzene;bromine Chemical compound [Br].C1=CC=CC=C1 CPWPJLJWUXOOAB-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中医药技术领域,特别涉及一种具有降尿酸功效的中药组合物及其制备方法和应用。该中药组合物由土茯苓、元胡、平卧菊三七和大麦苗制成。本发明经科学组方,将土茯苓、元胡、平卧菊三七和大麦苗组合使用后,具有显著的降尿酸功效,其降尿酸功效好于土茯苓、平卧菊三七或大麦苗单独使用的功效,可用于治疗痛风。临床试验结果显示本发明中药制剂总有效率达98%。
Description
技术领域
本发明涉及中医药技术领域,特别涉及一种具有降尿酸功效的中药组合物及其制备方法和应用。
背景技术
随着人们生活水平的提高和饮食习惯的改变,近年来,我国高尿酸血症和痛风的发病率呈逐年攀升趋势。高尿酸血症是由于嘌呤代谢紊乱和/或尿酸排泄障碍而导致血尿酸超过正常值的一种疾病,临床上不表现任何症状。而当人体长期处于高尿酸血症的情况下,尿酸即以钠盐的形式沉淀在关节、软组织、软骨和肾脏中,引起人体器官和组织病变,导致痛风,引发严重的并发症,包括痛风性关节炎、痛风性肾脏病变、痛风性肾结石、痛风性心脏病、痛风性高血压病等,病人出现关节痛、肾绞痛或血尿等症状。
目前治疗高尿酸血症和痛风的药物主要有非布索坦、别嘌醇、秋水仙碱、苯溴马隆、丙磺舒等。体内尿酸的生成与嘌呤代谢有关,在嘌呤代谢的最后步骤中,次黄嘌呤在黄嘌呤氧化还原酶(XOR)的作用下生成黄嘌呤,再进一步生成尿酸,非布索坦和别嘌醇是XOR的抑制剂,这两种药物通过高度选择性地作用于该氧化酶,减少体内尿酸合成,降低尿酸浓度,从而有效治疗通风疾病;秋水仙碱通过减低白细胞活动和吞噬作用及减少乳酸形成从而减少尿酸结晶的沉积,减轻炎性反应,而起止痛作用;苯溴马隆和丙磺舒通过抑制肾小管对尿酸盐的主动再吸收,增加尿酸盐的排泄而降低血中尿酸盐的浓度,缓解或防止尿酸盐结节的生成,减少关节的损伤,促进已形成的尿酸盐的溶解。虽然这些药物对于治疗痛风都具有较好的疗效,但在临床中都表现出一定的毒副作用,其中,非布索坦的不良反应包括肝功能异常、腹泻、头痛、关节相关征和症状及肌骨骼/结缔组织症状;别嘌醇常见皮疹、腹泻腹痛、低热、暂时性转氨酶升高或粒细胞减少等不良反应;秋水仙碱有剧毒,常见恶心、呕吐、腹泻、腹痛、胃肠反应、血尿、少尿、对骨髓有直接抑制作用、引起粒细胞缺乏、再生障碍性贫血等;苯溴马隆可致粒细胞减少;丙磺舒常见胃肠道反应、皮疹、发热等不良反应,长期使用这几种药物给患者带来极大的痛苦,威胁健康,影响生活质量。因此,开发新型的治疗高尿酸血症及痛风的药物依然是目前药学研究的热点。
发明内容
有鉴于此,本发明提供了一种具有降尿酸功效的中药组合物及其制备方法和应用。该中药组合物具有显著的降尿酸功效,可有效治疗痛风。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种中药组合物,由土茯苓、元胡、平卧菊三七和大麦苗制成。
土茯苓,为百合科植物光叶菝葜的干燥根茎,其为多年生常绿攀缘状灌木,多生于山坡或林下。入药部分只选择其干燥后的根茎。常于夏、秋二季采挖,除去须根,洗净后干燥入药;或趁鲜切成薄片后干燥、入药。味甘、淡,性平。有解毒,除湿,通利关节之功效,主要用于梅毒及汞中毒所致的肢体拘挛,筋骨疼痛;湿热淋浊,带下,痈肿,瘰疬,疥癣。土茯苓中含有土花茎皂甙,能增加尿酸盐排泄,排除蛋白尿,恢复胃功能的作用。《本草纲目》记载“健脾胃,强筋骨,去风湿,利关节,止泄泻,治拘挛骨痛”等作用。
元胡又名延胡索、玄胡,为罂粟科紫堇属多年生草本植物,与白术、芍药、贝母等并称“浙八味”,为大宗常用中药。元胡史载于《开宝本草》,性温,味辛苦,入心、脾、肝、肺,是活血化瘀、行气止痛之妙品,尤以止痛之功效而著称于世。李时珍在《本草纲目》中归纳元胡有“活血,理气,止痛,通小便”四大功效,并推崇元胡“能行血中气滞,气中血滞,故专治一身上下诸痛”。元胡富含生物碱,其中四氢巴马亭(乙素)对痛风病引起的疼痛有很好消肿止痛作用。
平卧菊三七,属于菊科菊三七属,攀援草本,有臭气,茎匍匐,淡褐色或紫色,有条棱,无毛或幼时有柔毛,有分枝;叶具柄。平卧菊三七在中国分布广泛,主产广东、海南、贵州、云南。平卧菊三七营养价值丰富,是一种药食兼可的独特植物,它和现在人们食用的木耳菜同属。食味柔滑,清香可口。可清炒、凉拌、氽汤,茎叶切碎作饺子、包子的馅颇具香味,煮泡饭的味道尤佳。其叶也可生吃,或取鲜叶开水冲泡当茶饮,如把叶子晒干泡水更是别有一番风味。平卧菊三七嫩茎叶营养丰富,其蛋白质、氨基酸、总糖、脂肪含量分别为1.24%、0.87%、1.5%、0.79%,膳食纤维含量为2.40克/100克,维生素C含量为11.2毫克/100克,富含有机钙,是中老年人补钙的绿色食品,还含有丰富的有机酸成分及黄酮类化合物。平卧菊三七的药用价值主要体现在以下几个方面:1、平卧菊三七主要食用嫩茎叶,具有清热解毒、止血止咳、减少血管紫癜、提高人体免疫力和抗病毒能力;泻火、凉血、消炎、生津等功效,对于肿病有一定的疗效。2、平卧菊三七全身都是宝,经安全性评价研究,平卧菊三七是一种无毒级的优质特种保健蔬菜,根茎是中成药上佳的原材料。其作菜食用或药用,可以补钙、抗病毒、抗感冒,提高免疫力等功效,外用对带状疱疹、各种皮炎、烫伤、烧伤及无名肿痛均有良好的疗效,还可以止血、止痛、止痒及护肤保湿抗衰老。3、平卧菊三七据《中国中草药汇编》记载,其具有通经活络,散瘀消肿,活血生肌的作用。对风热热闭证,肢体关节红肿热痛,屈伸不利均有良好的作用。其中含有大量的黄酮,绿原酸,类固酸,脂肪酸,半萜类物质等活性成分。长期服用可以改善痛风患者部位疼痛,肿胀,晨僵等症状,遏制关节病变加重或恶化,调节嘌呤合成酶和嘌呤抑制酶的活性,减少体内嘌呤的合成,同时调节尿酸代谢,促进尿酸排泄。
大麦苗为禾本科植物大麦的幼苗。光滑无毛,直立,叶鞘松弛抱茎。两侧有较大的叶耳;叶舌膜质,叶片扁平。穗状花序长3-8cm(芒除外),颖线状披针形,微具短柔毛。大麦苗中所含的维生素、矿物质及蛋白质是人类与动物的必需营养。1939年,干燥后的大麦苗作为“可接受食品”得到了美国医学会食品委员会的认可。随后,合成的营养素被加入各种食品中,复合维生素受到广泛欢迎。大麦苗所榨的汁中富含β-胡萝卜素,维生素B1、B2、B6、B12,泛酸和叶酸及矿物元素钾、钙、铁、磷、镁等。其他成分包括叶绿素、氨基酸、蛋白质、纤维素和生物酶。素食者通过补充大麦苗可以避免发生维生索B12缺乏症。大麦苗粉是碱性植物之王,可保全酸碱平衡,其富含钾,钙,镁及各种维生素,矿物质,对尿酸高的病人,长期服用具有很好的降低尿酸值的作用。
本发明将土茯苓、元胡、平卧菊三七和大麦苗组合使用后,具有显著的降尿酸功效,其降尿酸功效好于土茯苓、平卧菊三七或大麦苗单独使用的功效。其中,元胡并不具有降尿酸值的作用,但其可以使土茯苓、平卧菊三七和大麦苗的降尿酸功效得到提升。
在本发明中,大麦苗为新鲜大麦苗。
作为优选,以重量份计,由土茯苓800~1200份、元胡600~800份、平卧菊三七1500~2000份和大麦苗1000~1500份制成。
在本发明提供的一实施例中,以重量份计,该中药组合物由土茯苓1050份、元胡750份、平卧菊三七1950份和大麦苗1200份制成。
在本发明提供的另一实施例中,以重量份计,该中药组合物由土茯苓800份、元胡600份、平卧菊三七2000份和大麦苗1500份制成。
在本发明提供的另一实施例中,以重量份计,该中药组合物由土茯苓1200份、元胡800份、平卧菊三七1500份和大麦苗1000份制成。
本发明还提供了该中药组合物的制备方法,包括:将土茯苓、元胡、平卧菊三七进行醇提,得到醇提物;将大麦苗粉碎,与醇提物进行混合,得到中药组合物。
作为优选,该中药组合物的制备方法具体为:
将土茯苓、元胡、平卧菊三七混合,加入相当于原料重量5~10倍的质量百分比浓度为30%~90%的乙醇水溶液进行回流提取,共提取2~3次,每次2~3小时,合并提取液,过滤,浓缩,干燥,得到醇提物;
将大麦苗干燥、粉碎、杀菌,得到大麦苗粉;
将醇提物和大麦苗粉混合,得到中药组合物。
在本发明提供的实施例中,该中药组合物的制备方法具体为:
将土茯苓、元胡、平卧菊三七混合,加入相当于原料重量5倍的质量百分比浓度为50%的乙醇水溶液进行回流提取,共提取2次,每次3小时,合并提取液,过滤,浓缩,干燥,得到醇提物;
将大麦苗干燥、粉碎、杀菌,得到大麦苗粉;
将醇提物和大麦苗粉混合,得到中药组合物。
作为优选,浓缩采用减压真空浓缩的方式。
作为优选,干燥采用喷雾干燥或冷冻干燥的方式。本发明醇提物采用喷雾干燥的方式进行干燥,本发明大麦苗采用冷冻干燥的方式进行干燥。
作为优选,大麦苗采用气流粉碎的方式进行粉碎。
本发明还提供了该中药组合物在制备治疗高尿酸血症和/或痛风的药物或保健食品中的应用。
本发明还提供了一种药物,包括本发明提供的中药组合物。该中药组合物由土茯苓、元胡、平卧菊三七和大麦苗制成。
作为优选,药物的剂型为口服液、颗粒剂或胶囊剂。但药物的剂型并非限定于此,本领域技术人员认可的剂型均在本发明的保护范围之内。
在本发明提供的实施例中,药物的剂型为颗粒剂,颗粒剂包括本发明的中药组合物、粘合剂和填充剂。
在本发明提供的实施例中,粘合剂为羟丙甲纤维素,填充剂为淀粉。
作为优选,以重量份计,该颗粒剂中包括:本发明中药组合物80~100份、淀粉20~40份、羟丙甲纤维素0.1~1份。本发明颗粒剂还可以包括其它可行的辅料,本发明在此不做限定。
在本发明提供的实施例中,该颗粒剂的制备方法为:将本发明中药组合物与淀粉、羟丙甲纤维素水溶液进行混合,制粒,干燥,整粒,过60目筛,得到颗粒剂。
在本发明提供的实施例中,羟丙甲纤维素水溶液的质量百分比浓度为3%。
本发明还提供了一种保健食品,包括本发明提供的中药组合物。该中药组合物由土茯苓、元胡、平卧菊三七和大麦苗制成。
本发明提供了一种具有降尿酸功效的中药组合物及其制备方法和应用。该中药组合物由土茯苓、元胡、平卧菊三七和大麦苗制成。本发明至少具有如下优势之一:
1、本发明经科学组方,将土茯苓、元胡、平卧菊三七和大麦苗组合使用后,具有显著的降尿酸功效,其降尿酸功效好于土茯苓、平卧菊三七或大麦苗单独使用的功效,可用于治疗痛风。其中,元胡并不具有降尿酸值的作用,但其可以使土茯苓、平卧菊三七和大麦苗的降尿酸功效得到提升。
2、本发明的中药组合物及其制剂具有取材简易,成本低,效果确切,服用周期短,副作用小,见效快,不易反复发作,有效率高等特点。解决了目前市场上治疗尿酸值高和痛风的产品不理想,产品成本高,毒副作用大,服用周期长,容易反复发作的弊端。本发明通过多年的科学研究和临床实验,本组方的产品在临床效果上达到了令人满意的结果,显效率达到了64%,总有效率达98%,且组方简单,效果确切。
3、本发明产品制备工艺简单,值得广泛推广。
附图说明
图1示提取物干粉的制备工艺流程;
图2示颗粒剂制备工艺流程。
具体实施方式
本发明公开了一种具有降尿酸功效的中药组合物及其制备方法和应用,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明提供的具有降尿酸功效的中药组合物及其制备方法和应用中所用原料或辅料均可由市场购得。
下面结合实施例,进一步阐述本发明:
实施例1中药组合物的制备
取中药材土茯苓350kg、元胡250kg、平卧菊三七650kg,用相当于原料重量的5倍的50%乙醇回流提取,共提取2次,每次3小时,合并提取液,过滤,减压浓缩得流浸膏,经喷雾干燥得提取物干粉。
另取大麦苗400kg,通过冷冻干燥,汽流粉碎,杀菌即得大麦苗干粉。
将提取物干粉和大麦苗干粉混合,得到中药组合物。
提取物干粉的制备工艺流程见图1。
实施例2中药组合物的制备
取中药材土茯苓800kg、元胡600kg、平卧菊三七2000kg,用相当于原料重量的5倍的50%乙醇回流提取,共提取2次,每次3小时,合并提取液,过滤,减压浓缩得流浸膏,经喷雾干燥得提取物干粉。
另取大麦苗1500kg,通过冷冻干燥,汽流粉碎,杀菌即得大麦苗干粉。
将提取物干粉和大麦苗干粉混合,得到中药组合物。
实施例3中药组合物的制备
取中药材土茯苓1200kg、元胡800kg、平卧菊三七1500kg,用相当于原料重量的5倍的50%乙醇回流提取,共提取2次,每次3小时,合并提取液,过滤,减压浓缩得流浸膏,经喷雾干燥得提取物干粉。
另取大麦苗1000kg,通过冷冻干燥,汽流粉碎,杀菌即得大麦苗干粉。
将提取物干粉和大麦苗干粉混合,得到中药组合物。
对比例1土茯苓提取物的制备
取中药材土茯苓1000kg,用相当于原料重量的5倍的50%乙醇回流提取,共提取2次,每次3小时,合并提取液,过滤,减压浓缩得流浸膏,经喷雾干燥得土茯苓提取物干粉。
对比例2平卧菊三七提取物的制备
取中药材平卧菊三七1000kg,用相当于原料重量的5倍的50%乙醇回流提取,共提取2次,每次3小时,合并提取液,过滤,减压浓缩得流浸膏,经喷雾干燥得平卧菊三七提取物干粉。
对比例3大麦苗干粉的制备
取大麦苗1000kg,通过冷冻干燥,汽流粉碎,杀菌即得大麦苗干粉。
对比例4中药组合物的制备
取中药材土茯苓350kg、平卧菊三七650kg,用相当于原料重量的5倍的50%乙醇回流提取,共提取2次,每次3小时,合并提取液,过滤,减压浓缩得流浸膏,经喷雾干燥得提取物干粉。
另取大麦苗400kg,通过冷冻干燥,汽流粉碎,杀菌即得大麦苗干粉。
将提取物干粉和大麦苗干粉混合,得到中药组合物。
试验例1降尿酸功效试验
取实施例1-3、对比例1-4进行降尿酸功效的验证,具体试验方法为:
随机选取350名志愿者,志愿者年龄为25~50岁,皆为尿酸值高的患者。将志愿者随机分为7组,每组50人。各组志愿者分别服用各实验例和对比例的干粉,每次10克,每天三次,服用一个月,比较尿酸值。
结果如下:
表1中药组合物及提取物的降尿酸效果
试验结果可见:本发明实施例1-3的降尿酸有效率显著高于对比例1-4,显效率达到了64%,有效率达到了98%。表明,将土茯苓、元胡和平卧菊三七组合使用后的降尿酸效果更好。
其中,元胡并不具有降尿酸值的作用,但其可以使土茯苓、平卧菊三七和大麦苗的降尿酸功效得到提升。
实施例4中药颗粒剂的制备
取实施例1的中药组合物90kg、淀粉30kg进行混合,混合的时间为30~45分钟,加入3%羟丙甲纤维素水溶液15~20L进行搅拌,用颗粒机进行制粒,制粒后干燥,干燥后再进行整粒。过60目筛,除去粉末部分,再将颗粒进行包装即得。颗粒剂制备工艺流程见图2。
实施例5中药颗粒剂的制备
取实施例2的中药组合物90kg、淀粉30kg进行混合,混合的时间为30~45分钟,加入3%羟丙甲纤维素水溶液15~20L进行搅拌,用颗粒机进行制粒,制粒后干燥,干燥后再进行整粒。过60目筛,除去粉末部分,再将颗粒进行包装即得。
实施例6中药颗粒剂的制备
取实施例3的中药组合物90kg、淀粉30kg进行混合,混合的时间为30~45分钟,加入3%羟丙甲纤维素水溶液15~20L进行搅拌,用颗粒机进行制粒,制粒后干燥,干燥后再进行整粒。过60目筛,除去粉末部分,再将颗粒进行包装即得。
试验例2人体降尿酸功效试验
随机选取300名志愿者,志愿者年龄为25~50岁,皆为尿酸值高,有痛风的患者。将志愿者随机分为6组,每组50人。各组志愿者分别服用实施例4颗粒剂、土茯苓颗粒剂(对比例1土茯苓提取物按实施例4方法制得的颗粒剂)、平卧菊三七颗粒剂(对比例2平卧菊三七提取物按实施例4方法制得的颗粒剂)、大麦苗颗粒剂(对比例3大麦苗粉按实施例4方法制得的颗粒剂),以及市售痛风灵和玉竹兰葛茶。实施例4颗粒剂、土茯苓颗粒剂、平卧菊三七颗粒剂、大麦苗颗粒剂的服用方法相同,服用量:每袋12克,每天3次,每次一袋;痛风灵和玉竹兰葛茶按说明书方法服用。服用方法:40~60℃温开水冲服。服用一个月,比较尿酸值,调查有效率。
试验结果如下:
表2各组产品降尿酸效果
结果表明,服用本发明产品的志愿者中,有98%的志愿者的尿酸值有显著下降,而对比例中各单剂效果和市场产品的效果则远不及本发明。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种中药组合物,其特征在于,由土茯苓、元胡、平卧菊三七和大麦苗制成。
2.根据权利要求1所述的中药组合物,其特征在于,以重量份计,由土茯苓800~1200份、元胡600~800份、平卧菊三七1500~2000份和大麦苗1000~1500份制成。
3.如权利要求1或2所述中药组合物的制备方法,其特征在于,包括:将土茯苓、元胡、平卧菊三七进行醇提,得到醇提物;将大麦苗粉碎,与所述醇提物进行混合,得到所述中药组合物。
4.根据权利要求3所述的制备方法,其特征在于,所述制备方法具体为:
将土茯苓、元胡、平卧菊三七混合,加入相当于原料重量5~10倍的质量百分比浓度为30%~90%的乙醇水溶液进行回流提取,共提取2~3次,每次2~3小时,合并提取液,过滤,浓缩,干燥,得到醇提物;
将大麦苗干燥、粉碎、杀菌,得到大麦苗粉;
将所述醇提物和所述大麦苗粉混合,得到所述中药组合物。
5.如权利要求1或2所述中药组合物在制备治疗高尿酸血症和/或痛风的药物或保健食品中的应用。
6.一种药物,其特征在于,包括如权利要求1或2所述中药组合物。
7.根据权利要求6所述的药物,其特征在于,所述药物的剂型为口服液、颗粒剂或胶囊剂。
8.根据权利要求6或7所述的药物,其特征在于,所述药物的剂型为颗粒剂,所述颗粒剂包括如权利要求1或2所述中药组合物、粘合剂和填充剂。
9.根据权利要求8所述的药物,其特征在于,所述粘合剂为羟丙甲纤维素,所述填充剂为淀粉。
10.一种保健食品,其特征在于,包括如权利要求1或2所述中药组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611255698.7A CN106492073A (zh) | 2016-12-30 | 2016-12-30 | 一种具有降尿酸功效的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611255698.7A CN106492073A (zh) | 2016-12-30 | 2016-12-30 | 一种具有降尿酸功效的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106492073A true CN106492073A (zh) | 2017-03-15 |
Family
ID=58334771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611255698.7A Pending CN106492073A (zh) | 2016-12-30 | 2016-12-30 | 一种具有降尿酸功效的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106492073A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096502A (zh) * | 2018-01-20 | 2018-06-01 | 南阳仲景百信医药科技有限公司 | 一种降尿酸代用茶及其制备方法 |
CN109646481A (zh) * | 2019-02-25 | 2019-04-19 | 韩合旭 | 防治痛风的药食同源制剂 |
CN109718272A (zh) * | 2019-02-25 | 2019-05-07 | 韩合旭 | 防治高血压的药食同源制剂 |
CN110731962A (zh) * | 2018-07-18 | 2020-01-31 | 中国医学科学院药物研究所 | 小檗碱、黄连碱或其活性代谢产物、及其盐在预防和/或治疗尿酸性肾病药物中的应用 |
CN112426461A (zh) * | 2020-12-22 | 2021-03-02 | 江西中医药大学 | 一种治疗痛风性关节炎的中药组合物及其制备方法与应用 |
CN115350177A (zh) * | 2022-08-23 | 2022-11-18 | 暨南大学 | 提取物的降尿酸功能及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293928A (zh) * | 2010-06-22 | 2011-12-28 | 天津市石天药业有限责任公司 | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 |
CN104366636A (zh) * | 2014-10-30 | 2015-02-25 | 袁丁 | 一种平卧菊三七复合制剂及制备方法及应用 |
CN105832794A (zh) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用 |
-
2016
- 2016-12-30 CN CN201611255698.7A patent/CN106492073A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293928A (zh) * | 2010-06-22 | 2011-12-28 | 天津市石天药业有限责任公司 | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 |
CN104366636A (zh) * | 2014-10-30 | 2015-02-25 | 袁丁 | 一种平卧菊三七复合制剂及制备方法及应用 |
CN105832794A (zh) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108096502A (zh) * | 2018-01-20 | 2018-06-01 | 南阳仲景百信医药科技有限公司 | 一种降尿酸代用茶及其制备方法 |
CN110731962A (zh) * | 2018-07-18 | 2020-01-31 | 中国医学科学院药物研究所 | 小檗碱、黄连碱或其活性代谢产物、及其盐在预防和/或治疗尿酸性肾病药物中的应用 |
CN110731962B (zh) * | 2018-07-18 | 2022-05-20 | 中国医学科学院药物研究所 | 小檗碱、黄连碱或其活性代谢产物、及其盐在预防和/或治疗尿酸性肾病药物中的应用 |
CN109646481A (zh) * | 2019-02-25 | 2019-04-19 | 韩合旭 | 防治痛风的药食同源制剂 |
CN109718272A (zh) * | 2019-02-25 | 2019-05-07 | 韩合旭 | 防治高血压的药食同源制剂 |
CN112426461A (zh) * | 2020-12-22 | 2021-03-02 | 江西中医药大学 | 一种治疗痛风性关节炎的中药组合物及其制备方法与应用 |
CN112426461B (zh) * | 2020-12-22 | 2022-02-08 | 江西中医药大学 | 一种治疗痛风性关节炎的中药组合物及其制备方法与应用 |
CN115350177A (zh) * | 2022-08-23 | 2022-11-18 | 暨南大学 | 提取物的降尿酸功能及其制备方法 |
CN115350177B (zh) * | 2022-08-23 | 2023-06-06 | 暨南大学 | 提取物的降尿酸功能及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106492073A (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN106177183A (zh) | 一种包含青钱柳叶、绿茶和桑叶的降血糖保健组合物 | |
CN106176953A (zh) | 一种包含青钱柳叶、罗汉果和桑叶的降血糖保健组合物 | |
CN107095995B (zh) | 一种治疗胃炎和胃溃疡的药物组合物及制备方法 | |
CN109170476A (zh) | 含有菊苣的保健食品 | |
CN104873826A (zh) | 一种可清肺祛湿的茶饮及其制备方法 | |
CN102266511B (zh) | 一种小儿消暑健胃咀嚼片及其制备方法 | |
CN106962921A (zh) | 一种健康饮食添加粉及其制备方法 | |
CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
CN105056103A (zh) | 一种辅助降血脂降胆固醇的馒头及其制备方法 | |
CN106491760A (zh) | 具有降血压作用的瑶药足疗包及其制备方法 | |
CN102512642B (zh) | 一种治疗脾胃病的药物组合物及其用途 | |
CN105327262A (zh) | 一种治疗小儿便秘的中药配方及其制备方法 | |
CN104855647A (zh) | 一种人参抗三高保健茶 | |
CN112914009A (zh) | 一种阳虚体质保健固体饮料及其制备方法 | |
CN105012743A (zh) | 具有降血压功效的养生粥 | |
CN1267143C (zh) | 一种复方龟鳖参铁皮枫斗养阴胶囊和冲剂制备方法 | |
CN108142930A (zh) | 用于调理湿热体质的中药膏方及其加工方法 | |
CN107007782A (zh) | 一种用于治疗牙痛和口腔溃疡的特效中药组合物 | |
CN106434176A (zh) | 具有降三高功能的保健酒及其生产方法 | |
CN105288066A (zh) | 治疗动脉粥样硬化的方剂及制备方法 | |
CN105435189A (zh) | 中药组合物在制备治疗急性胃炎药物中的用途 | |
CN104857242A (zh) | 一种治疗小儿疳积的健脾消食剂及制备方法 | |
CN104971157A (zh) | 一种治疗脚气的外搽粉及制法 | |
CN105616558A (zh) | 急性细菌性痢疾清热利湿药膏 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |
|
RJ01 | Rejection of invention patent application after publication |